Relationship Between Cytogenetic Complexity and Peritumoral Edema in High-Grade Astrocytoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The purpose of the study is to reveal the association of cytogenetic complexity and peritumoral edema volume (PTEV) and its prognostic significance in high-grade astrocytoma patients by culturing patient tumor cells. Methods: Twenty-seven high-grade astrocytoma patients were divided into three groups according to karyotype complexity: normal, non-complex karyotype (NCK), and complex karyotype (CK). Endothelial growth factor receptor (EGFR) amplification was detected by FISH, and its association with chromosome 7 abnormalities was analyzed. Mean PTEV of each group was compared by ANOVA to evaluate the relationship between PTEV and cytogenetic complexity. Results: The PTEV of patients in normal (n=6), NCK (n=8), and CK (n=13) groups were 24.52±17.73, 34.26±35.04, and 86.31±48.7 cm3, respectively (P=0.005). Ten out of 11 patients with EGFR amplification showed abnormalities in chromosome 7. The mean PTEV of EGFR-amplified and non-amplified groups were 80.4±53.7 and 41.3±37.9 cm3, respectively (P=0.035). The average survival of patients with PTEV less than 90 cm3 was 30.52±26.11 months, while in patients with PTEVs over or equal to 90 cm3, it was 10.83±5.53 months (P=0.007). Conclusions: The results show an association of complex karyotype with the PTEV of high-grade astrocytoma. EGFR amplification plays a significant role in the formation of peritumoral edema, causing PTEV to increase, which is related with survival. This implies that cytogenetic karyotype can be applied as a prognostic factor.
Abstract
Background: The purpose of the study is to reveal the association of cytogenetic complexity and peritumoral edema volume (PTEV) and its prognostic significance in high-grade astrocytoma patients by culturing patient tumor cells. Methods: Twenty-seven high-grade astrocytoma patients were divided into three groups according to karyotype complexity: normal, non-complex karyotype (NCK), and complex karyotype (CK). Endothelial growth factor receptor (EGFR) amplification was detected by FISH, and its association with chromosome 7 abnormalities was analyzed. Mean PTEV of each group was compared by ANOVA to evaluate the relationship between PTEV and cytogenetic complexity. Results: The PTEV of patients in normal (n=6), NCK (n=8), and CK (n=13) groups were 24.52±17.73, 34.26±35.04, and 86.31±48.7 cm3, respectively (P=0.005). Ten out of 11 patients with EGFR amplification showed abnormalities in chromosome 7. The mean PTEV of EGFR-amplified and non-amplified groups were 80.4±53.7 and 41.3±37.9 cm3, respectively (P=0.035). The average survival of patients with PTEV less than 90 cm3 was 30.52±26.11 months, while in patients with PTEVs over or equal to 90 cm3, it was 10.83±5.53 months (P=0.007). Conclusions: The results show an association of complex karyotype with the PTEV of high-grade astrocytoma. EGFR amplification plays a significant role in the formation of peritumoral edema, causing PTEV to increase, which is related with survival. This implies that cytogenetic karyotype can be applied as a prognostic factor.
참고문헌 (24)
- Ohgaki H, "Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas", J Neuropathol Exp Neurol, 64, pp.479~489 (2005)
- Heimberger AB, "Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients", Clin Cancer Res, 11, pp.1462~1466 (2005)
- Stupp R, "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma", N Engl J Med, 352, pp.987~996 (2005)
- Walid MS, "Prognostic factors for long-term survival after glioblastoma", Perm J, 12, pp.45~48 (2008)
- Barker FG, "EGFR overexpression and radiation response in glioblastoma multiforme", Int J Radiat Oncol Biol Phys, 51, pp.410~418 (2001)
- Lu-Emerson C, "Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma", J Clin Oncol, 33, pp.1197~1213 (2015)
- Das P, "A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival", J Clin Neurosci, 18, pp.66~70 (2011)
- Gan HK, "The EGFRvIII variant in glioblastoma multiforme", J Clin Neurosci, 16, pp.748~754 (2009)
- Hartmann C, "Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations", Clin Cancer Res, 19, pp.5146~5157 (2013)
- Hyuk Hur, "Cerebellar Glioblastoma Multiformein an Adult", 대한신경외과학회지, 43(4), pp.194~197 (2008), 대한신경외과학회
- Jain R, "Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers", Radiology, 267, pp.212~220 (2013)
- Montgomery RM, "EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation", Arq Neuropsiquiatr, 73, pp.561~568 (2015)
- Shiraishi S, "Influence of p53 mutations on prognosis of patients with glioblastoma", Cancer, 95, pp.249~257 (2002)
- Lopez-Gines C, "Association of chromosome 7, chromosome 10 and EGFR gene amplification in glioblastoma multiforme", Clin Neuropathol, 24, pp.209~218 (2005)
- Reardon D, "Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges", Neuro Oncol, 16(S8), pp.viii7~viii13 (2014)
- Lal A, "Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion", Cancer Res, 62, pp.3335~3339 (2002)
- Schoenegger K, "Peritumoral edema on MRI at initial diagnosis: an independent prognostic factor for glioblastoma?", Eur J Neurol, 16, pp.874~878 (2009)
- Smith JS, "PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme", J Natl Cancer Inst, 93, pp.1246~1256 (2001)
- Krex D, "Long-term survival with glioblastoma multiforme", Brain, 130, pp.2596~2606 (2007)
- Lawrence YR, "Improving prognosis of glioblastoma in the 21st century: who has benefited most?", Cancer, 118, pp.4228~4234 (2012)
- Schmidt MC, "Impact of genotype and morphology on the prognosis of glioblastoma", J Neuropathol Exp Neurol, 61, pp.321~328 (2002)
- Aghi M, "Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma", Clin Cancer Res, 11, pp.8600~8605 (2005)
- Maire CL, "Molecular pathologic diagnosis of epidermal growth factor receptor", Neuro Oncol, 16(S8), pp.viii1~viii6 (2014)
- Maity A, "Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3’-kinase and distinct from that induced by hypoxia", Cancer Res, 60, pp.5879~5886 (2000)